Univadis COVID-19 Weekly Overview 5 June

  • Ben Gallarda
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Due to the rapidly changing nature of the COVID-19 pandemic, we at Univadis would like to share with you the most impactful and clinically relevant articles across our network from the past week.

Some of these articles are only published in local languages, but we have tried to summarize the key points for you below and link to the original source of each article in case you would like to read more, with languages other than English noted in brackets.

This is a snapshot of emerging best-practices during a rapidly evolving pandemic. Any and all information currently available related to COVID-19 is subject to change as more details become available. Some of the information below may also be contradicted by local or global health authorities. You can find all of the most up-to-date COVID-19 coverage on your local Univadis site or smartphone application.

We hope this information will be useful to your ongoing medical care for all patients, whether directly involved with COVID-19 or not.

  1. According to a medrXiv preprint, even in the heavily affected Lombardy region of Italy, rates of exposure to SARS-CoV-2 vary greatly. Serological tests of nearly 4000 employees of 7 hospitals showed IgG positivity rates from 3% (Varese) to 43% (Bergamo). Of those testing positive, 10% were asymptomatic and 20% had only 1 or 2 symptoms. Exposure via family contact likely played an important role as well.
  2. As of June 3, Spain [Spanish] has reported zero deaths for COVID-19 for 2 consecutive days. In addition, a Univadis editorial [Spanish] applauds all kinds of Spanish doctors for coming together to deal with COVID-19: “In these months many specialists have come back into contact with the essence of their profession. They have connected with Hippocrates and Galen, with Marañón and Sir William Osler.”
  3. A retrospective German case study looked at 33 HIV-positive patients with COVID-19. All of the patients were on antiretroviral therapy (ART), 25 had a mild disease course, 2 severe and 8 critical, with 14 being admitted to the hospital. An 82-year-old man detectable viral load, a patient with low CD4 cell count and a patient with multiple comorbidities were the only ones who died. These findings suggest that HIV-positive patients on ART do not generally have an increased risk with COVID-19.
  4. A study of T cells from 20 adults who were PCR-positive for SARS-CoV-2 but not hospitalized showed significant CD4+ cells split evenly between targeting the spike protein and other epitopes. CD8+ cell responses were also found in the majority of those studies. These results allow for optimism that it may be possible to create effective vaccines against SARS-CoV-2.
  5. The UK has launched a trial of lipid ibuprofen for reducing the severity of lung injury progression in patients with COVID-19 in London. This trial will test hospitalized adult patients to see if the treatment will limit worsening respiratory failure and need for mechanical ventilation.